-
2 weeks ago | 
journals.sagepub.com | Jeffrey CL Looi |Gin S Malhi |Steve Kisely
Editorial independence safeguards the rights of authors and readers to freely speak and be heard (Brakoulias and Malhi, 2024; Hoey, 2008; Looi et al., 2024b). This underpins the key goals of medical journals to strive for academic excellence and progress the science of care (Malhi and Brakoulias, 2022). It is enacted by editors having freedom to make decisions about the scientific publication record (Bhui et al., 2025).
-
3 weeks ago | 
cambridge.org | Gin S Malhi |Joan Marsh |Dost Ongur |Fiammetta Cosci
Published online by Cambridge University Press: 24 April 2025Gin S. Malhi [Opens in a new window] ,Joan Marsh [Opens in a new window] ,Dost Ongur [Opens in a new window] ,Fiammetta Cosci [Opens in a new window] ,John H. Krystal [Opens in a new window] ,Gregers Wegener [Opens in a new window] ,Susan Redline [Opens in a new window] ,Carmine M.
-
1 month ago | 
onlinelibrary.wiley.com | Peter Tyrer |Helen Tyrer |Gin S Malhi
1 Introduction It is well established that the course of bipolar disorder may be preceded by other affective symptoms, and these may precede the first episode of hypomania or mania by many years. Apart from genetic predisposition and childhood instability of mood, there are few data examining affective symptoms and personality status in those that develop bipolar disorder.
-
Feb 13, 2025 | 
onlinelibrary.wiley.com | Erica Bell |Gin S Malhi |Gracie Meng-Cin Tsai |Ching-Wen Hung
Academic Department of Psychiatry, Faculty of Medicine and Health, Kolling Institute, Northern Clinical School, The University of Sydney, Sydney, New South Wales, AustraliaFaculty of Philosophy, Oxford Uehiro Centre for Practical Ethics, University of Oxford, Oxford, UK
-
Oct 16, 2024 | 
cambridge.org | Hugo D. Critchley |Derek Tracy |Gin S Malhi |Laith Alexander
Hostname: page-component-788cddb947-kc5xbTotal loading time: 0Render date: 2024-10-16T08:52:23.916ZHas data issue: falsehasContentIssue false Published online by Cambridge University Press: 16 October 2024Hugo D. Critchley [Opens in a new window] ,Derek K. Tracy [Opens in a new window] ,Gin S. Malhi [Opens in a new window] ,Laith Alexander [Opens in a new window] ,David S. Baldwin [Opens in a new window] ,Jonathan Cavanagh [Opens in a new window] ,Samuel R.
-
Oct 4, 2024 | 
cambridge.org | Gin S Malhi |Erica Bell
Britain's historical contributions to the promotion of lithium as a treatment for bipolar disorder have occurred episodically, somewhat like the illness it best treats. At different times over the past century and a half, British research into the effects of lithium and the opinions of leading figures in psychiatry and psychopharmacology on its clinical efficacy have both promoted and hindered its use.
-
Aug 31, 2024 | 
onlinelibrary.wiley.com | Gin S Malhi |Erica Bell |Uyen Le |Philip Boyce
In a case of long-standing, complicated major depression, esketamine was added to typical therapeutic agents used to overcome non-response. This case exemplifies how even in severe depression that has failed to respond to extensive treatment with diverse interventions, substantive improvements remain possible. Thus, depression described as ‘treatment resistant’ should not necessarily be regarded as irremediable.
-
Aug 29, 2024 | 
onlinelibrary.wiley.com | Gin S Malhi |Erica Bell
Corresponding Author Gin S.
-
Aug 22, 2024 | 
cambridge.org | Gin S Malhi
The Feature articleReference Bastidas-Bilbao, Castle, Gupta, Stergiopoulos and Hawke1 in this issue of the BJPsych is the product of a somewhat unique situation in Canada, where, although legislation has been passed to provide medical assistance in dying (MAiD) to those with a mental illness, its implementation has been deferred because of widespread concerns regarding its provision to so-called vulnerable populations.
-
May 23, 2024 | 
onlinelibrary.wiley.com | Gin S Malhi |Uyen Le |Erica Bell |Cornelia Kaufmann
Adding esketamine to lamotrigine was explored with promising results in a clinical trial. Lamotrigine, a bipolar disorder mood stabiliser, occasionally used to treat major depression, shares mechanisms of action with esketamine suggesting combinatorial benefits. Whether this effect is synergistic, augmenting or neither is discussed to advance clinically meaningful examination.
